{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:02:50Z","timestamp":1761541370107},"reference-count":31,"publisher":"Impact Journals, LLC","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,25]]},"DOI":"10.18632\/oncotarget.16238","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T01:59:26Z","timestamp":1489629566000},"page":"50187-50192","source":"Crossref","is-referenced-by-count":10,"title":["Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma"],"prefix":"10.18632","volume":"8","author":[{"given":"G\u00e1bor","family":"Somlyai","sequence":"first","affiliation":[{"name":"HYD, LLC for Cancer Research & Drug Development, Budapest, Hungary, European Union"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Que","family":"Collins","sequence":"additional","affiliation":[{"name":"CignatureHealth Metabolic Clinic, Santa Monica, CA, USA"},{"name":"EPIGENIX Foundation, El Segundo, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle J.","family":"Meuillet","sequence":"additional","affiliation":[{"name":"The University of Arizona Cancer Center, Tucson, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patel","family":"Hitendra","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic P.","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, Hyperbaric Biomedical Research Laboratory, University of South Florida, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3 G.","family":"Boros","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Los Angeles School of Medicine, Westwood, CA, USA"},{"name":"Los Angeles Biomedical Research Institute (LABIOMED) at the Harbor-UCLA Medical Center, Torrance, CA, USA"},{"name":"SiDMAP, LLC, Culver City, CA, USA"},{"name":"UCLA Clinical and Translational Science Institute, Torrance, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate-a new oral targeted therapy","volume":"346","author":"Antman","year":"2002","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.8211127","article-title":"A new five-year plan for the U.S. Human Genome Project","volume":"262","author":"Galas","year":"1993","journal-title":"Science"},{"key":"3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/526029a","article-title":"Human Genome Project: Twenty-five years of big biology","volume":"526","author":"Collins","year":"2015","journal-title":"Nature"},{"key":"4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CCO.0000000000000318","article-title":"Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?","volume":"28","author":"Awada","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1056\/NEJM200207043470116","article-title":"Imatinib and chronic-phase leukemias","volume":"347","author":"Cascante","year":"2002","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M105796200","article-title":"Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells","volume":"276","author":"Boros","year":"2001","journal-title":"J Biol Chem"},{"key":"7","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.18632\/oncotarget.14321","article-title":"Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma","volume":"8","author":"Dallaglio","year":"2017","journal-title":"Oncotarget"},{"key":"8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2337\/db15-1382","article-title":"PPAR antagonist Gleevec improves insulin sensitivity and promotes the browning of white adipose tissue","volume":"65","author":"Lee","year":"2016","journal-title":"Diabetes"},{"key":"9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.tem.2015.09.003","article-title":"Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?","volume":"26","author":"Tsatsoulis","year":"2015","journal-title":"Trend Endocrin Metab"},{"key":"10","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia","volume":"353","author":"Gherlinzoni","year":"2005","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11306-011-0300-9","article-title":"Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75","volume":"8","author":"Boros","year":"2012","journal-title":"Metabolomics"},{"key":"12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11306-013-0555-4","article-title":"Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells","volume":"10","author":"Meuillet","year":"2014","journal-title":"Metabolomics"},{"key":"13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.molcel.2014.05.008","article-title":"Compartmentalized NADPH Synthesis, Intramolecular Deuterium Disequilibrium and Water Pools of Mammalian CellsTracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells","volume":"55","author":"Lewis","year":"2014","journal-title":"Mol Cell"},{"key":"14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mehy.2015.11.016","article-title":"Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle","volume":"87","author":"Somlyai","year":"2016","journal-title":"Med Hypotheses"},{"key":"15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.exphem.2014.02.006","article-title":"Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib","volume":"4","author":"Stoklosa","year":"2014","journal-title":"Exp Hematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gross","year":"2005","journal-title":"Drug Metabolism and Disposition"},{"key":"17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Lydon","year":"2000","journal-title":"J Clin Invest"},{"key":"18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl","volume":"21","author":"Manley","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1021\/ml100164p","article-title":"Drawing the PDB: Protein\u2212Ligand Complexes in Two Dimensions","volume":"1","author":"Rarey","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"20","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/db13-0368","article-title":"AMPK: A Target for Drugs and Natural Products with Effects on Both Diabetes and Cancer","volume":"62","author":"Hardie","year":"2013","journal-title":"Diabetes"},{"key":"21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00129785-200505050-00002","article-title":"Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications","volume":"5","author":"Boros","year":"2005","journal-title":"Am J Pharmacogenomics"},{"key":"22","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells","volume":"15","author":"Serkova","year":"2009","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1476-5381.2009.00345.x","article-title":"Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells","volume":"158","author":"Serkova","year":"2009","journal-title":"Br J Pharmacol"},{"key":"24","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells","volume":"10","author":"Serkova","year":"2004","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0306312715612146","article-title":"Constructing failure in big biology: The socio-technical anatomy of Japan's Protein 3000 Project","volume":"46","author":"Fukushima","year":"2016","journal-title":"Soc Stud Sci"},{"key":"26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11306-005-1103-7","article-title":"Metabolic targeted therapy of cancer: current tracer technologies and future drug design strategies in the old metabolic network","volume":"1","author":"Boros","year":"2005","journal-title":"Metabolomics"},{"key":"27","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jama.2016.11076","article-title":"What happens when underperforming big ideas in research become entrenched?","volume":"316","author":"Ioannidis","year":"2016","journal-title":"JAMA"},{"key":"28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jama.2015.7725","article-title":"Seven Questions for Personalized Medicine","volume":"314","author":"Paneth","year":"2015","journal-title":"JAMA"},{"key":"29","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1038\/537S63a","article-title":"The precision-oncology illusion","volume":"537","author":"Prasad","year":"2016","journal-title":"Nature"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now284","article-title":"What to eat or what not to eat - that is still the question","author":"Somlyai","year":"2017","journal-title":"Neuro-Oncology"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.5772\/57432","volume-title":"Pancreatic Cancer - Insights into Molecular Mechanisms and Novel Approaches to Early Detection and Treatment","author":"McCall","year":"2014"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T12:38:43Z","timestamp":1658839123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":31,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2017,7,25]]}},"alternative-id":["16238","28418852"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16238","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}